Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021283 | 0.89 | MAOB (0.48) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2968592 | 0.89 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL2974015 | 0.88 | MAOB (0.49) | MAOBMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL2969127 | 0.87 | MAOB (0.53) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL810860 | 0.85 | MAOB (0.52) | MAOBMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL2957105 | 0.83 | MAPT (0.52) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL2963008 | 0.83 | KDM4E (0.48) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2960977 | 0.80 | RAB9A (0.44) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2964875 | 0.80 | MEN1 (0.48) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2970843 | 0.79 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MTNR1A 4309/4885MTNR1B 4306/4885F2 2150/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | MTNR1A 4309/4885MTNR1B 4306/4885F2 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.